NCT00606866View on ClinicalTrials.gov

MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

June 30, 2008

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

placebo

Placebo for four weeks

DRUG

Sorafenib

Sorafenib 200 mg twice daily

DRUG

Sorafenib

Sorafenib, 400 mg twice daily

Trial Locations (1)

60637

The University of Chicago, Chicago

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Chicago

OTHER

NCT00606866 - MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter